

## Index

- Acinetobacter baumannii*, pneumonia  
     pathogen 303
- actin cytoskeleton  
     ADP-ribosylation by toxins 193, 194  
     covalent modification by bacterial  
         toxins 193–195  
     disruption by bacterial pathogens  
         374–376  
     modulation by bacteria 220–221  
     modulation by ERM proteins 189  
     polymerization 188  
     polymerizing toxin of *Vibrio*  
         *cholerae* 194–195
- actin filaments (microfilaments) 12, 13  
     in polarized epithelial cells 12–14  
     role in endocytosis 12–14
- adenocarcinoma, link with *Helicobacter*  
     *pylori* 328–330
- adherens junctions 12–15
- adhesins  
     afimbrial 160–162, 165–173, 174  
     fimbrial 159, 160, 165–173, 174
- adhesion molecules, secretion by epithelial  
     cells 112–113
- Aeromonas hydrophila*, type II secretion  
     system 65
- afimbrial adhesins 160–161  
     integrin-binding 161–162  
     Opa proteins 167–173, 174  
     used together with fimbrial  
         adhesins 165–173, 174
- Agrobacterium tumefaciens*  
     plasmid virulence factors 34–35  
     VirB/D4 system 66, 75–76, 77
- AIDS 103–104
- airway epithelial cells *see* alveoli, lung  
     epithelial cells, lung epithelium,  
     respiratory tract
- alveoli  
     epithelial cells 4, 8  
     *Streptococcus pneumoniae* infection 8
- antibiotics  
     effects on colon bacteria 7  
     resistance  
         encoded by transposons 39–40  
         transmission by plasmids 34
- anti-inflammatory effects  
     NF- $\kappa$ B activation 253  
     probiotics 255–256
- antimicrobial peptides, in the lung 306–308
- anti-virulence genes 45–46  
     *cadA* inactivation in *Shigella* spp. 47–49, 50  
     *Escherichia coli ompT* gene 50–51
- apical junctional complex 14–16  
     bacterial attacks 14–16
- arachidonic acid  
     metabolism 269–270, 272  
         regulation of responses and pathways  
             270, 285–287
- metabolites  
     eicosanoids 269–270, 272, 273–274  
     hepoxilins 270, 273–274, 285–287

- arachidonic acid (*cont.*)
  - leukotrienes 270, 283–287
  - pro- and anti-inflammatory actions 271–272
  - prostaglandins 270, 275–279, 285–287
  - metabolizing enzymes in bacteria 287–288
  - role in bacterial pneumonia 270, 283–285
  - role in cystic fibrosis 280–283
- bacillary dysentery 46–51
- Bacillus anthracis*
  - immune response avoidance 44
  - plasmid-encoded toxins 35
  - plasmid virulence factors 34–35
- Bacillus thuringiensis*, plasmid-encoded toxins 35
- bacterial adhesins
  - afimbrial adhesins 160–161
  - fimbrial adhesins 159, 160
  - invasin 164–165
- bacterial adhesion
  - binding to epithelial cellular surfaces 356–363
  - importance in infectious diseases 158–159
  - tight adhesion to epithelial cells 158–159
- bacterial–epithelial interactions
  - intestinal epithelium and *Salmonella* Typhimurium 270, 272–276
  - pro-inflammatory responses 270, 272–285
  - Pseudomonas aeruginosa* and lung epithelium in cystic fibrosis 279–285
  - Streptococcus pneumoniae* and lung epithelium 270, 283–285
- bacterial genetics
  - horizontal gene transfer (HGT) 31–33
  - mutation and selection 31
- bacterial invasion mechanisms
  - arachidonic acid metabolizing enzymes 287–288
  - effector proteins 214–215, 216–218, 363–365
  - electrolyte transport disruption 379–380
  - endocytic membrane transport
    - exploitation 10–12
  - host actin cytoskeleton
    - modulation 220–221
  - host-cell receptor exploitation 356–363
  - lung epithelium 317–318
  - matrix-binding integrins 162–165
  - microtubules, use of 12
  - mimicry of host-cell proteins 214–215, 219
  - molecular manipulation of host epithelial cells 363–365
  - PRR evasion strategies 118–119
  - responses to host phagocytic cells 214–215, 218
  - Salmonella* Typhimurium 214–215, 221, 223, 224–225
  - Shigella flexneri* paradigm 217, 223, 225–227
  - specific interaction with host surface components 158–159
  - strategies to breach the epithelial barrier 214–215, 216–217, 218
  - tandem beta-zipper mechanism 213, 216
  - tight-junction disruption 220–221, 369–370, 374–377
  - trigger mechanism 213–216
  - Yersinia* paradigm 226
  - zipper mechanism 213, 216
- bacterial load
  - colonic lumen 7
  - small-intestinal lumen 5–6
- bacterial pathogens
  - challenges in colonizing host epithelia 158–159
  - differences between strains 38
  - effects on intestinal barrier
    - function 369–370
  - evolution
    - bacteriophage-mediated horizontal gene transfer (HGT) 35–38, 39
    - contributions of horizontal gene transfer (HGT) 33–43
    - convergent evolution among *Shigella* lineages 47–49, 50
    - horizontal gene transfer (HGT) processes 31–33
    - lysogenic conversion 35–39
    - mutation and selection 31
    - pathogenicity islands (PAIs) 40–42, 43

- plasmid transmission of virulence
    - factors 33–35
    - study of 30
    - transposable elements 39–40
  - evolution from commensals 43–49, 50, 51
    - colonizing a new niche 43–44
    - genome reduction 45–46
    - pathoadaptation 44–45
    - Shigella* spp. 46–49, 50, 51
  - variation in ability to colonize and cause disease 184–185
  - variety of means to cause host damage 185
- bacterial pneumonia 270, 283–285
  - etiology and epidemiology 302–304
  - pathogenesis and virulence
    - factors 304–305, 306
- bacterial secretion systems (Gram-negative bacteria) 60
  - type I 60–61, 62, 64
  - type II 64–66, 68
  - type III 66, 68–75
  - type IV 66, 75–80
  - type V 80–81, 85
- bacterial secretion systems (Gram-positive bacteria) 59–60
- bacterial toxins
  - phage-encoded genes 36, 38
  - physical organization 190–191, 192, 193
  - plasmid-encoded 35
- bacterial toxin targets
  - actin polymerization 188
  - actin polymerizing toxin of *Vibrio cholerae* 194–195
  - activation of Rho function 196–197
  - activation of Rho GTPases by GEF
    - mimics 198
  - ADP-ribosylation of actin by C2 toxins 194
  - BFT protease of E-cadherin 201
  - CagA and dephosphorylation of ezrin 201
  - cell signaling by Rho GTPases 188–189
  - cholera toxin ADP-ribosylation of
    - alpha-subunit of G<sub>s</sub> 202
  - covalent modification of actin 193–195
  - CPE association with tight junctions 201
  - cytotoxic necrotizing factor (CNF)
    - deamidation of Rho 196–197
  - dermonecrotizing toxin (DNT)
    - transglutamidation of Rho 197
  - epithelial tight junction disruption 201
  - ERM proteins 189, 200
  - ExoS ADP-ribosylation of ERM
    - proteins 200–201
  - ExoT ADP-ribosylation of Crk 199–200
  - ExoY as mimic of host adenylate cyclase 202
  - inactivation of Rho GTPases 195–196
  - inactivation of Rho GTPases by Rho GAP
    - mimics 198–199
  - large clostridial toxin glucosylation of
    - Rho 195–196
  - modulation of intracellular cAMP in mammals 202
  - modulation of Crk signaling
    - pathway 199–200
  - molecular organization of host
    - target 185–187, 190
  - non-covalent modification of Rho 197–199
  - polarized epithelium 190
  - Rac1 signal transduction by Crk
    - proteins 190
  - RNA function disruption in inhibition of
    - protein synthesis 203–204
  - Salmonella* cytotoxins 194
  - Shiga toxin deadenylation of rRNA 203
  - Shiga-toxin-producing *Escherichia coli* and hemolytic uremic syndrome 203–204
  - Shigella* activation of Crk signaling
    - pathway 200
  - signal transduction by heterotrimeric G-proteins 185–188
  - YopH phosphatase of focal adhesion
    - proteins 199
  - YopT cleavage at Rho C-terminus 196
- bacteriophage
  - attributable differences between strains 38
  - encoded virulence phenotypes 37, 38
  - evolution 38–39
  - lysogenic conversion of host
    - bacterium 35–38, 39
  - mediated bacterial pathogenesis 35–38, 39
  - mediated horizontal gene transfer (HGT) 32–33

- Bacteroides fragilis* toxin (BFT) 201  
 attack on apical junctional complex 14–15  
 disruption of intestinal barrier function 375
- Bartonella* spp., type IV secretion systems 75–76
- bioactive lipids 269–270, 272
- bladder  
 bacterial infections 9  
*see also* urinary tract infections; uroepithelium/urothelium
- Blau syndrome susceptibility 117–118
- Bordetella pertussis*  
 PT system 66, 75–76, 77, 78  
 type I secretion system 62  
 type V secretion systems 82  
 virulence factors encoded by pathogenicity islands (PAI) 42
- Borrelia hermsii*, immune response avoidance 44
- botulinum toxins, phage-encoded genes 36, 38
- bronchi, epithelial cells 8
- bronchioles, epithelial cells 8
- Brucella* spp., type IV secretion system 75–76
- Burkholderia pseudomallei*, type II secretion system 65
- C2 toxins, ADP-ribosylation of actin 193
- cadA* anti-virulence gene, inactivation in *Shigella* spp. 47–49, 50
- cadherins 15  
 use by bacteria 15
- CagA *Helicobacter pylori* virulence factor 337–338  
 effects on epithelial cell apoptosis 343  
 effects on host cell 338  
 effects on host cell junctions 341  
 geographic distribution of genetic variability 338–339, 341  
 link with severity of gastric diseases 338–339, 341  
 multiple functional domains
- Calobacter crescentus*, flagella 139–141
- cAMP, modulation by bacterial toxins 202
- Campylobacter jejuni*  
 flagellar export of non-flagellar proteins 147  
 microtubules for cell invasion 12  
 role of flagella in persistent infections 135–136
- cathelicidins 251–253
- Caulobacter crescentus*  
 type I secretion system 62  
 type IV secretion systems 75–76
- caveolae, role in endocytosis 11–12
- caveolin-mediated endocytosis 11–12
- CD14 (PRR) 103–104, 106–107
- CEACAM-binding adhesins and human mucosal colonization 169–173, 174
- CEACAM family of surface receptors 169–173, 174
- CF *see* cystic fibrosis
- chemical defenses, in the lung 306–308
- chemokines (chemotactic cytokines)  
 epithelial signaling pathways 316  
 produced in epithelial responses to bacteria 253, 254  
 secretion by epithelial cells 111–112, 113
- chemosensory system (bacteria) 131, 144–146
- chemotaxis, bacterial directional control 144–146
- Chlamydia trachomatis*  
 type V secretion system 82  
 use of caveolin-mediated endocytosis 11–12
- cholera toxin 9  
 ADP-ribosylation of the  $\alpha$ -subunit of  $G_s$  202  
 phage-encoded genes 36, 38  
 use of caveolin-mediated endocytosis 11–12
- chromosomal DNA in horizontal gene transfer (HGT) 32–33
- ciliary dyskinesia 12
- Citrobacter rodentium*, type III secretion system 72–73
- CLAN protein (PRR) 102
- clathrin-mediated endocytosis 11
- claudins 15–16

- Clostridium botulinum* toxins  
   phage-encoded genes 36, 38  
   rho inactivation by C3 toxin 12–14
- Clostridium difficile*  
   colitis pathogen 7  
   disruption of intestinal barrier  
     function 374–375  
   pathogenesis 184–185  
   rho inactivation by toxins 12–14  
   roles of flagella in infection 135  
   toxin glucosylation of Rho 195–196
- Clostridium diphtheriae*, infection of trachea  
   and bronchi 8
- Clostridium perfringens* enterotoxin  
   (CPE) 15–16, 201
- Clostridium tetani* 184–185
- CNF (cytotoxic necrotizing factor),  
   deamidation of Rho 196–197
- CNF1 (cytotoxic necrotizing factor type 1) in  
   UPEC infections 410–411, 412–413
- colitis due to *Clostridium difficile* overgrowth 7
- colon 4, 7
- colonizing a new niche 43–44
- commensal gut flora  
   abnormal immune response to 256–257  
   abnormal inflammatory response  
     to 256–257  
   lack of epithelial reactivity to 255–256
- commensals, pathogen evolution  
   from 43–49, 50, 51
- conjugation process of horizontal gene  
   transfer (HGT) 32–33
- conjugative transposons 39–40
- convergent evolution among *Shigella*  
   lineages 47–49, 50
- Corynebacterium diphtheriae*, pathogenic  
   evolution 36, 38
- Coxiella burnetii*, genome reduction 46
- Crk proteins, Rac1 signal transduction 190
- Crk signaling pathway, modulation by  
   bacterial toxins 199–200
- Crohn's disease 248–257, 271–272  
   epithelial barrier dysfunction 17–18,  
     20  
   link with Nod2 mutations 256–257  
   susceptibility 117–118
- cryptdins (alpha-defensins) 251–253
- cystic fibrosis  
   development of bacterial  
     pneumonia 303–304  
   genetic mutation responsible 280  
   link with *cftr* mutations 10  
   *Pseudomonas aeruginosa* interaction with  
     lung epithelium 279–285, 287–288  
   role of arachidonic acid and fatty acid  
     metabolism 280–283
- cystitis due to urinary tract infection 401
- cytokine production  
   epithelial responses to bacteria 253, 254  
   epithelial signaling pathways 316
- cytoskeleton, functions in polarized  
   epithelium 12–13, 14  
   see also actin cytoskeleton
- defensins 110–111, 251–253  
   impaired production in inflammatory  
     bowel disease 256–257
- disease susceptibility, effects of PRR  
   polymorphisms 117–118
- DNT (dermonecrotizing toxin),  
   transglutamidation of Rho 197
- drug resistance  
   encoded by transposons 39–40  
   transmission by plasmids 34
- duodenal ulcers, link with *Helicobacter*  
   *pylori* 328–330
- duodenum 5–6
- dynein, role in cilia motility 12
- dysentery (shigellosis) 46–51  
   see also *Shigella* spp.
- E. coli* see *Escherichia coli*  
   see also EHEC, EPEC, ETEC, UPECs
- E-cadherin  
   action of *Bacteroides fragilis* toxin (BFT) 201  
   cellular receptor for InlA 161  
   use by *Listeria monocytogenes* 15
- EHEC (enterohemorrhagic *Escherichia coli*)  
   attachment to host epithelial cells 360–363  
   differences between strains 38  
   disruption of intestinal barrier  
     function 374, 376–377  
   effectors and their roles in  
     pathogenesis 365–366, 369

- EHEC (enterohemorrhagic *Escherichia*) (*cont.*)  
   phage-encoded genes for Shiga toxins 36, 38  
   virulence factors encoded by PAI 42
- EHEC O157:H7 (enterohemorrhagic *Escherichia coli* O157:H7) 365–369
- NF-T3SS 68–70, 72–75
- pathogenic evolution 51
- type II secretion system 65
- eicosanoids 269–270, 272, 273–274
- electrolyte transport in epithelial cells 378–379  
   interference by bacterial pathogens 379–380  
   interference by host-derived products 380  
   link with intestinal barrier function 380–381
- endocytosis  
   caveolin-mediated 11–12  
   clathrin-mediated 11  
   exploitation by bacteria 10–12  
   in membrane transport 10–12  
   role of actin filaments (microfilaments) 12–14
- Enterobacter* infections of bladder and urethra 9
- Enterococcus faecalis*, association with urinary tract infections 401
- EPEC (enteropathogenic *Escherichia coli*) 72–75  
   attachment to host epithelial cells 360–363  
   disruption of epithelial tight junctions 374, 376–377  
   disruption of intestinal barrier function 374, 376–377  
   effectors and their roles in pathogenesis 365–366, 369  
   EPEC-induced MLC phosphorylation 17  
   fimbrial adhesins 159, 160  
   global regulation of virulence genes 45  
   possible role in MLCK upregulation 19–20  
   role of motility in infection 132–135  
   virulence factors encoded by pathogenicity islands 42
- epithelial barrier  
   dysfunction, MLCK-mediated mechanisms 16–18, 20  
   modulation by PRRs 115–117  
   regulation 16–18, 20
- epithelial cells  
   adhesion molecules secretion 112–113  
   antibacterial molecules 251–253  
   antimicrobial secretions 110–111  
   apical junctional complex 14–16  
   apoptosis  
     effects of *Helicobacter pylori* CagA 343  
     and NF- $\kappa$ B activation 254–255  
   bacterial exploitation of cellular processes 3  
   balance between pro- and anti-inflammatory responses 271–272  
   chemokine secretion 111–112, 113  
   cytokine/chemokine responses to bacteria 253, 254  
   electrolyte transport processes 378–379  
   host-derived disruptors of electrolyte transport 380  
   immune cell regulation 111–113  
   immunoregulatory cytokine secretion 112  
   integrin functions 14  
   interactions between 14–16  
   intercellular junctions 14–16  
   lack of reactivity to commensal microflora 255–256  
   pro-inflammatory mediators 253, 254  
   PRR-mediated responses 108–109  
   recognition of bacteria 310–315  
   regulation of PRR response 113–115, 116  
   responses to NF- $\kappa$ B activation 251–254, 255  
   transport processes disrupted by pathogens 379–380  
   variety of bacterial toxins which cause damage 185
- epithelial tight junctions 12–16  
   alteration by PRRs 115–117  
   binding sites for pathogens 377  
   barrier regulation 16–18, 20  
   disruption of proteins by pathogens 376–377  
   disruption via the actin cytoskeleton 374–376  
   effects of CagA 341  
   effects of inflammatory response 377–378  
   microbial receptors 360

- structure and functions 370–371, 374
- target for bacterial toxins 190, 201
- tight junction proteins 15–16
- epithelium
  - gastrointestinal tract 3–4, 7
  - respiratory tract 4, 7–8, 301
  - urinary tract
    - (uroepithelium/urothelium) 8–9
- ERM proteins
  - modulation by bacterial toxins 200
  - modulation of the actin cytoskeleton 189
- Erwinia chrysanthemi*
  - type I secretion systems 62
  - type II secretion system 65
  - type V secretion system 82
- Escherichia coli*
  - chemosensory system 144–146
  - close relationship to *Shigella* spp. 46–51
  - infections of bladder and urethra 9
  - LDC activity 47–49, 50
  - NF-T3SS 68–71, 72–75
  - ompT* anti-virulence gene 50–51
  - pathogenesis 184–185
  - plasmid-encoded toxins 35
  - plasmid transmission of virulence
    - factors 33–34, 35
  - regulation of flagellar gene
    - expression 142–143, 144
  - Shiga-toxin production and hemolytic
    - uremic syndrome 203–204
  - type I secretion systems 60–63, 64
  - type V secretion system 82
  - see also* EHEC; EPEC; ETEC; UPECs
- ETEC (enterotoxigenic *Escherichia coli* H10407)
  - transposon-encoded toxins 40
  - type II secretion system 65
- esophageal squamous epithelium 3–4, 5
- fimbrial adhesins 159, 160
  - used together with afimbrial
    - adhesins 165–173, 174
- flagella
  - bacterial chemosensory system 131
  - biogenesis via type III secretion
    - system 140, 141–142
  - chemotactic motility control 144–146
  - directional control of motility 131
  - export of non-flagellar proteins via type III
    - secretion system 147–149
  - flagellar gene expression
    - regulation 142–143, 144
  - means of adherence to epithelial cells 135
  - means of adherence to mucosa 135
  - number and arrangement 131
  - PRR detection of flagellar
    - expression 118–119
  - role in bacterial infections in mucosa 132, 133
  - role in initial colonization of host 132–135
  - role in persistent colonization of
    - hosts 135–137
  - role in *Proteus mirabilis* virulence 137–139
  - secretion pathway 131–132
  - structure and assembly 131–132, 140, 141–142
  - swarming of bacteria 137–139
  - type III secretion systems 131–132, 140, 141–142, 147–149
  - virulence factor 132–135
- flagellin
  - host surveillance system 139–141
  - methods of release 139–141
  - recognition by TLR5 131–132, 139–141, 313–314
  - type III secretion 139–141
- focal adhesion proteins, target of YopH
  - cytotoxin 199
- gastric cancer
  - link with effects of CagA 341
  - link with *Helicobacter pylori* 201, 328–330, 333–334
  - see also Helicobacter pylori*
- gastric diseases
  - geographic distribution and CagA
    - variability 338–339, 341
  - link with *Helicobacter pylori* 328–330
  - see also Helicobacter pylori*
- gastric mucosa, interaction with *Helicobacter pylori* 276–279
- gastric ulceration 201
  - link with *Helicobacter pylori* 328–330
  - see also Helicobacter pylori*

- gastritis 5, 201
  - link with *Helicobacter pylori* 328–330
  - see also *Helicobacter pylori*
- gastroenteritis see *Salmonella* Typhimurium
- gastrointestinal epithelial cells
  - adherence of bacteria to cellular surface 356–363
  - detection of bacteria on cellular surface 356–363
  - host-derived disruptors of electrolyte transport 380
  - interference in transport processes by pathogens 379–380
  - molecular manipulation by bacterial pathogens 363–365
- gastrointestinal epithelial tight junctions
  - disruption of proteins by pathogens 376–377
  - disruption via the actin cytoskeleton 374–376
  - effects of bacterial pathogens 369–370
  - effects of inflammatory response 377–378
  - structure and functions 370–371, 374
- gastrointestinal epithelium 3–4, 7
- gastrointestinal tract 3–4, 7
  - colon 4, 7
  - colonization by bacteria 356
  - esophageal squamous epithelium 3–5
  - functions 3
  - gastric columnar epithelium 4, 5
  - oral cavity squamous epithelium 3–4, 5
  - small intestine 4, 5–7
- genome reduction
  - for obligate intracellular lifestyle 46
  - pathoadaptive gene loss 45–46
- glucose absorption 9
- Gram-negative bacteria
  - membranes structure 60
  - Sec-dependent secretion pathway 60
  - secretion systems 60
  - type I secretion systems 60–61, 62, 64
  - type II secretion systems 64–66, 68
  - type III secretion systems 66, 68–75
  - type IV secretion systems 66, 75–80
  - type V secretion systems 80–81, 85
- Gram-positive bacteria
  - major types of surface proteins 60
  - Sec-dependent secretion pathway 59–60
  - secretion systems 59–60
- hemolytic uremic syndrome and *Escherichia coli* Shiga toxin 203–204, 365–369
- Haemophilus influenzae*
  - pneumonia pathogen 302–304
  - type V secretion system 82
- Helicobacter pylori*
  - acid resistance 330–331
  - binding to host mucus cells 332–333, 338
  - Cag PAI 337–338
  - Cag system 66, 75–76, 77, 78–79
  - CagA effects on epithelial cell apoptosis 343
  - cagA gene 277
  - CagA multiple functional domains
  - CagA toxin 201
  - CagA virulence factor 337–338
  - carcinogenesis induced by 333–334
  - chemotaxis 332
  - discovery of 328–330
  - distribution within gastric mucus layer 331–332
  - exploitation of human gastric niche 327, 328
  - flagella and motility 331–332
  - gastric disease link 328–330
  - geographic distribution of CagA genetic variability 338–339, 341
  - geographic distribution of severe gastric diseases 338–339, 341
  - immune system modulation by VacA 336–337
  - infection in the stomach 5
  - interaction with gastric mucosa 276–279
  - intracellular persistence 333–334
  - persistence mechanisms 333–334
  - possible role in MLCK upregulation 19–20
  - PRR evasion strategies 118–119
  - role of flagella in persistent infections 135, 136–137
  - subversion of host innate immune system 330–331
  - type V secretion system 82



- VacA virulence factor 334–337  
 virulence factors encoded by PAI 42  
 world infection rates 328–330  
 $\alpha$ -hemolysin toxin (Hly $\alpha$ ), in UPEC  
   infections 409–411, 412–413  
 hepoxilins 270, 273–274, 285–287  
 heterotrimeric G-proteins, signal  
   transduction 185–188  
 heterotrimeric G $_s$ -protein, ADP-ribosylation  
   by cholera toxin 202  
 HGT *see* horizontal gene transfer in bacteria  
 HIV infection 103–104  
 horizontal gene transfer in bacteria 30  
   bacteriophage-mediated 32–33  
   chromosomal DNA transfer 32–33  
   conjugation process 32–33  
   contributions to bacterial pathogen  
     evolution 33–43  
   evidence in *Shigella* spp. 46–51  
   evolution of 46–51  
   plasmid transfer 32–33  
   plasmid transmission of virulence  
     factors 33–35  
   processes in bacteria 31–33  
   transduction process 32–33  
   transformation process 32–33  
   transposable elements 32–33  
 host–bacterial interactions, mediation by  
   PRRs 99–108  
 host-cell invasion  
   fate of bacteria after invasion 228–229  
   later stages of bacteria–host cell  
     interaction 223, 227–228  
   *Salmonella* Typhimurium trigger  
     mechanism 214–215, 221, 223,  
     224  
   *Shigella flexneri* paradigm 217, 223,  
     225–227  
   *Yersinia* paradigm 230–231  
 host defenses, against bacterial lung  
   pathogens 301–302  
 host gastric cells, effects of *Helicobacter pylori*  
   CagA 338, 341  
 host–pathogen interactions 184–185  
   bacterial enzymes metabolize arachidonic  
     acid 287–288  
 host recognition of flagellin 139–141  
 host responses  
   induced by bacteria 214–215, 219  
   to pilus-mediated attachment 167  
   to UPEC attachment 407–409  
 host specificity, bacterial adhesin–host  
   receptor pairs 161  
 human mucosal colonization,  
   CEACAM-binding adhesins 169–173,  
   174  
 HUS *see* hemolytic uremic syndrome and  
   *Escherichia coli* Shiga toxin  
 IBD *see* inflammatory bowel disease  
 IgA trafficking 10–11  
 ileum 5–6  
 immune cells, regulation by epithelial  
   cells 111–113  
 immune responses  
   abnormal response to commensal gut  
     flora 256–257  
   epithelial production of pro-inflammatory  
     mediators 253, 254  
   regulation 113–115, 116  
 immune system  
   activation by flagellin 139–141  
   bacterial adaptations to avoid 44  
   exploitation by *Streptococcus*  
     *pneumoniae* 10–11  
   innate component 99–101, 111–113,  
     330–331  
   modulation by *Helicobacter pylori*  
     VacA 336–337  
   PRR regulation of adaptive immunity 113  
 immunodeficiency disorders and abnormal  
   NF- $\kappa$ B activation 256–257  
 immunoregulatory cytokines, secretion by  
   epithelial cells 112  
 infectious diseases, importance of bacterial  
   adhesion 158–159  
 inflammation, actions of arachidonic acid  
   metabolites 271–272  
 inflammation-associated tumor  
   growth 254–255  
 inflammatory bowel disease (IBD) 256–257  
   risk of intestinal malignancy 254–255  
 inflammatory response  
   regulation 113–115, 116

- inflammatory response (*cont.*)
  - abnormal response to commensal gut flora 256–257
  - effects of cell death and tissue damage 254–255
  - effects on epithelial tight junctions 377–378
  - modulation by bacterial effector proteins 363–365
  - uroepithelium 403
- innate immune system 99–101
  - coordination by PRRs 111–113
  - subversion by *Helicobacter pylori* 330–331
- iNOS expression, response to NF- $\kappa$ B
  - activation 252–253
- insertion sequences (IS) 39
- integrin-binding afimbrial adhesins 161–162
- integrins
  - distribution within epithelial cells 165
  - engagement by enteropathogenic *Yersinia* spp. 164–165
  - mediation of cell interactions 14
- interferon gamma, role in MLCK
  - up-regulation 17–18, 20
- interferon-inducible PRR expression 115
- internalin A (InlA)-E-cadherin
  - interaction 161
- intestinal barrier function
  - disruption by pathogens 369–370, 374–377
  - link with electrolyte transport processes 380–381
- intestinal epithelium, interaction with *Salmonella* Typhimurium 270, 272–276
- intestinal inflammation, chronic 256–257
- intracellular pathogens 44
- invasin 164–165
- jejunum 5–6
- junctional adhesion molecules 16
- Kartagener's syndrome 7–8, 12
- Klebsiella oxytoca*, type II secretion system 64–65, 66
- Klebsiella pneumoniae*, pneumonia pathogen 303
- Klebsiella* spp.
  - association with urinary tract infections 401
  - infections of bladder and urethra 9
- larynx, epithelial cell types 7–8
- LDC (lysine decarboxylase) activity in *Escherichia coli* and *Shigella* 47–49, 50
- Legionella pneumophila*
  - Dot/Icm system 66, 75–76, 77, 79–80
  - immune response avoidance 44
  - infection susceptibility 117–118
  - role of motility in initial infection 132–135
  - type II secretion system 65
  - virulence factors encoded by PAIs 42
- Legionella* spp., pneumonia
  - pathogens 302–304
- legionnaires' disease susceptibility 117–118
  - see also* *Legionella pneumophila*
- leukotrienes, role in host defenses 270, 283–287
- lipid bilayer membranes, structure and functions 269
- lipopolysaccharide
  - receptors 99–101, 104, 105, 106–107
  - recognition by TLR4 312–313
- Listeria monocytogenes*
  - exploitation of host receptor cells 359–360
  - InlA-mediated interaction with epithelial cells 161
  - PRR evasion strategy 118–119
  - use of E-cadherin 15
  - virulence factors encoded by PAIs 42
- LPS *see* lipopolysaccharide
- lung epithelial cells
  - antimicrobial peptides and chemical defenses 306–308
  - innate host defenses against lung pathogens 301–302
  - inflammatory response and bacterial clearance 308–310
  - Nod receptors 315
  - pro-inflammatory signaling pathways 316
  - pro-inflammatory signaling regulation 316–317
  - receptor shedding 316–317
  - recognition of bacteria 310–315

- responses to bacteria 306–307, 308, 310
  - signaling through TNFR1 314–315
  - TLRs 310–314
- lung epithelium
  - bacterial invasion and lung damage 317–318
  - interaction with *Pseudomonas aeruginosa* in cystic fibrosis 279–285
  - interaction with *Streptococcus pneumoniae* 270, 283–285
- lysogenic conversion of host
  - bacterium 35–38, 39
  - virulence phenotypes 37, 38
- MALT lymphoma, link with *Helicobacter pylori* 328–330
- matrix-binding integrins, bacterial
  - internalization via 162–164
- meningitis 37
- microtubules
  - functions in polarized epithelial cells 12, 13
  - use for bacterial invasion 12
- MLC (myosin II regulatory light chain)
  - phosphorylation 16–18, 20
- MLCK (myosin light chain kinase)
  - MLCK-mediated epithelial barrier dysfunction 16–18, 20
  - PIK inhibitor of MLCK 17
  - transcription factors 18–20
  - upregulation of MLCK protein expression 17–18, 20
- Moraxella catarrhalis*, type V secretion system 82
- MRSA (methicillin resistant *Staphylococcus aureus*) 303
- mucociliary clearance 7–8, 12
- mutation and selection in bacteria 31
- Mycobacterium leprae*, genome reduction 46
- Mycobacterium tuberculosis*, immune response avoidance 44
- Na<sup>+</sup>-nutrient cotransporters 9
- Neisseria gonorrhoeae*
  - fimbrial adhesins 159, 160
  - immune response avoidance 44
  - use of fimbrial and afimbrial adhesins 165–173, 174
- Neisseria meningitidis*
  - lysogenic conversion 37
  - type V secretion system 82
  - use of fimbrial and afimbrial adhesins 165–173, 174
- NF-κB
  - family of transcription factors 245
  - role in antimicrobial defense 244
- NF-κB activation
  - abnormalities
    - immunodeficiency disorders 256–257
    - inflammatory bowel disease 256–257
  - anti-apoptotic effect 254–255
  - anti-inflammatory effects 253–254
  - by bacteria-derived signals 246, 247–251
  - by bacterial effector proteins 249–250
  - by bacterial surface molecules
  - by bacterial toxins 249–250
  - clinical implications of abnormal activation 256–257
  - epithelial production of antibacterial molecules 251–253
  - functional responses in epithelial cells 251–254, 255
  - iNOS upregulation response 252–253
  - Nod pathway 248
  - pro-inflammatory effects 253, 254
  - TLR pathway 247–248
  - tumor growth 254–255
- NF-κB-dependent transcription, stages 245–246, 247
- NF-κB inhibitors 255–256, 257
- NF-T3SSs *see* non-flagellar type III secretion systems
- Nod proteins 101–102
  - airway epithelial cell Nod receptors 315
  - in the uroepithelium 403
  - pathway of NF-κB activation 248
- Nod2 mutations, link with Crohn's disease 256–257
- non-flagellar type III secretion systems (NF-T3SSs) 66, 68–75
  - cytoskeletal effects 74
  - effectors 66, 69, 70, 73–75
  - regulators and chaperones 66, 70, 71–72
  - secretion apparatus and needle 66, 70–71
  - subversion of the immune system 74–75

- non-flagellar type III secretion (*cont.*)
  - translocation apparatus 66, 70, 72–73
  - vesicular trafficking 75
- occludins 16
- ompT* anti-virulence gene in *Escherichia coli* 50–51
- Opa (opacity associated) proteins 167–168
  - cellular receptors targeted 168–173, 174
- oral cavity squamous epithelium 3–4, 5
- oxyntic (acid-producing) mucosa 4, 5
- PAIs (pathogenicity islands) 40–42, 43
  - evolution 41–43
  - Helicobacter pylori* Cag PAI 337–338
  - Shigella* spp. 46–47
  - uropathogenic *Escherichia coli* strains 403–404, 405
- PAMPs, recognition by PRRs 100–101
- Paneth cells 251–253
- paracellular permeability increase, induced by bacteria 17
- Pasteurella haemolytica*, type V secretion system 82
- pathoadaptation 44–45
  - mutation by gene loss 45–46
- peptic ulcers *see Helicobacter pylori*
- Peyer's patches (terminal ileum) 5–7
- PIK (MLCK inhibitor) 17
- pili (fimbriae) 159, 160
- pilus-mediated cell attachment 166–167
- PKR (protein kinase R) 102
- plasmids
  - evolution 35
  - gene transfer in horizontal gene transfer (HGT) 33–35
  - plasmid transfer in horizontal gene transfer (HGT) 32–33
- pneumonia
  - community acquired 303
  - development in cystic fibrosis 303–304
  - hospital acquired 303
  - ventilator associated 303
  - see also* bacterial pneumonia
- polarized epithelium
  - functions of microtubules 12, 13
  - functions of the cytoskeleton 12–13, 14
  - generalized structure 9
  - role in secretion 10
  - target for bacterial toxins 190
  - vectorial transport 9–10
- polymeric immunoglobulin receptor 9, 10–11
- Porphyromonas gingivalis*, attack on apical junctional complex 14–15
- probiotics 252–253
  - beneficial effects 255–256
- pro-inflammatory responses
  - bacterial-epithelial interactions 270, 272–285
  - effects of NF- $\kappa$ B activation 253, 254
- gastric mucosa and *Helicobacter pylori* 276–279
- intestinal epithelium and *Salmonella* Typhimurium 270, 272–276
- mediators produced by epithelial cells 253, 254
- Pseudomonas aeruginosa* and lung epithelium in cystic fibrosis 279–285
- Streptococcus pneumoniae* and lung epithelium 270, 283–285
- prostaglandins 270, 275–279, 285–287
- protein synthesis, inhibition by bacterial toxins 203–204
- Proteus mirabilis*
  - association with urinary tract infections 9, 401
  - role of swarming in urinary tract infection 137–139
- PRRs (pattern-recognition receptors)
  - adaptive immunity regulation 113
  - antimicrobial secretions mediation 110–111
  - CD14 103–104, 106–107
  - CLAN protein 102
  - epithelial barrier modulation 115–117
  - epithelial cell regulation of PRR response 113–115, 116
  - epithelial cell responses mediation 108–109
  - flagellar expression detection 118–119
  - flagellin recognition 139–141
  - host–bacterial interactions mediation 99–108

- host defense mechanisms  
     mediation 108–109, 117
- human PRR polymorphisms 117–118
- innate immune responses  
     mediation 108–109, 111–113
- interferon-inducible PRR expression 115
- intracellular PRRs 101–103
- microbial evasion strategies 118–119
- Nod proteins 101–102
- PAMP recognition 100–101
- PKR 102
- PRR ligands definition 104–105, 106
- PRR signaling 107–108
- receptor types 99–101
- RNA helicases 102–103
- soluble PRRs 103–104
- spatial strategy to control PRR  
     response 114–115, 116
- TLR coreceptors 106–107
- TLRs (Toll-like receptors) 100–101
- Pseudomonas* spp.  
     ExoS cytotoxin 198–199, 200–201  
     ExoT cytotoxin 198–200  
     ExoY cytotoxin 202
- Pseudomonas aeruginosa* pneumonia  
     pathogen 302–305, 306  
     actions in cystic fibrosis 279–285, 287–288  
     fimbrial adhesins 159, 160  
     NF-T3SS 68–70, 73–75  
     opportunistic pathogen 184–185  
     role of motility in initial infection 132–135  
     type II secretion system 64–65  
     type III secretion system 317–318
- Pseudomonas aeruginosa* strain PA1169,  
     enzyme to metabolize arachidonic  
     acid 287–288
- Pseudomonas fluorescens*, type I secretion  
     system 60–63
- Pseudomonas syringae*, NF-T3SS 68–70
- pyelonephritis 9, 401
- Rac1 signal transduction by Crk proteins 190
- Ralstonia solanacearum*, NF-T3SS 68–70
- respiratory tract 4, 7–8  
     alveoli 4, 8  
     bronchi 8  
     bronchioles 8
- Clostridium diphtheria* infection 8
- epithelial cells of the larynx 7–8
- mucociliary clearance 7–8
- respiratory epithelium 301
- trachea 8  
     *see also* lung epithelial cells; lung epithelium
- Rhizobium etli*, type IV secretion  
     systems 75–76
- Rho  
     activation by bacterial toxins 196–197  
     deamidation by cytotoxic necrotizing factor  
     (CNF) 196–197  
     glucosylation by large clostridial  
     toxins 195–196  
     non-covalent modification by bacterial  
     toxins 197–199  
     targets of bacterial toxins 7, 12–14  
     transglutamidation by dermonecrotizing  
     toxin 197  
     YopT cleaves at the C-terminus 196
- Rho GTPases  
     activation by GEF mimics 198  
     cell signaling 188–189  
     inactivation by bacterial toxins 195–196  
     inactivation by Rho GAP mimics 198–199
- Rickettsiae, genome reduction 46
- RNA function, disruption by bacterial  
     toxins 203–204
- RNA helicases 102–103
- rRNA, deadenylation by Shiga toxin 203
- Salmonella enterica*  
     NF-T3SSs 68–71, 72–75  
     phage-encoded virulence factor 38  
     type V secretion system 82
- Salmonella* spp.  
     inhibition of NF- $\kappa$ B 255–256  
     intracellular pathogens 44  
     motility in initial infection 132–135  
     PRR evasion strategies 118–119  
     *Salmonella* plasmid virulence (*spv*) gene  
     cluster 229–230  
     SopE cytotoxin 198  
     SptP cytotoxin 198–199  
     SpvB cytotoxin 194  
     targeting of rho 12–14  
     virulence factors encoded by PAIs 42

- Salmonella* Typhimurium  
 actin-binding proteins enhancement of  
   entry 223, 224–225  
 fate of bacteria after invasion 228–229  
 flagellar biogenesis 140, 141–142  
 interaction with intestinal epithelium 270,  
   272–276  
 later stages of host-cell interaction 223,  
   227–228  
 plasmid virulence gene cluster 229–230  
 regulation of flagellar gene  
   expression 142–143, 144  
*Salmonella* plasmid virulence (*spv*) gene  
   cluster 229–230  
 trigger mechanism of host-cell  
   invasion 214–215, 221, 223, 224  
 Sec-dependent secretion pathway  
   Gram-negative bacteria 60  
   Gram-positive bacteria 59–60  
*Serratia marcescens*  
   type I secretion systems 60–63  
   type V secretion system 82  
 Shiga-like toxins, use of clathrin-mediated  
   endocytosis 11  
 Shiga toxin (Stx) 365–369  
   deadenylation of rRNA 203  
   phage-encoded genes 36, 38  
   use of clathrin-mediated endocytosis 11  
 Shiga-toxin-producing *Escherichia coli* and  
   hemolytic uremic syndrome 203–204  
*Shigella boydii* 46–51  
*Shigella dysenteriae* 46–51  
   toxin 184–185, 203  
*Shigella flexneri* 46–51  
   lysogenic conversion 36–37  
   paradigm of host cell invasion 217, 223,  
     225–227  
   phage-encoded virulence factors 38  
   type IV secretion systems 75–76  
   type V secretion system 82  
*Shigella sonnei* 46–51  
*Shigella* spp.  
   *cadA* anti-virulence gene  
     inactivation 47–49, 50  
   close relationship to *Escherichia coli* 46–51  
   convergent evolution among  
     lineages 47–49, 50  
   Crk signaling pathway activation 200  
   epithelial tight junction disruption 377  
   evidence of horizontal gene transfer (HGT)  
     evolution 46–51  
   host receptor cell exploitation 358–359  
   intracellular pathogens 44  
   NF- $\kappa$ B inhibition 255–256  
   NF-T3SS 68–71  
   *ompT* anti-virulence gene not  
     present 50–51  
   pathogenic evolution from  
     commensals 46–49, 50, 51  
   pathogenicity islands (PAIs) 42, 46–47  
   plasmid transmission of drug resistance 34  
   plasmid virulence factors 34–35  
   PRR evasion strategy 118–119  
   virulence factors encoded by PAI 42  
   virulence genes regulation 44–45  
   virulence plasmid 46–47  
 shigellosis 46–51  
   *see also Shigella* spp.  
 signal transduction  
   heterotrimeric G-proteins 185–188  
   role of cadherins 15  
 small intestine 4, 5–7  
   duodenum 5–6  
   functionally distinct sections 5–6  
   ileum 5–6  
   jejunum 5–6  
   luminal bacterial load 5–6  
   M-cells 4, 6–7  
   Peyer's patches 5–7  
   specialized epithelial cell types 4, 6–7  
   tissue architecture 4, 6  
   undifferentiated crypt cells 4, 6–7  
   villi 4, 6–7  
 sperm motility 12  
*Staphylococcus aureus*  
   integrin-binding afimbrial  
     adhesins 161–162  
   internalization via matrix-binding  
     integrins 162–164  
   phage-encoded genes for toxins 36, 38  
   plasmid-encoded toxin 35  
   pneumonia pathogen 302–305, 306  
*Staphylococcus saprophyticus*, urinary tract  
   infections 401

- Staphylococcus* spp., infection  
susceptibility 117–118
- stomach  
antrum 5  
cardia 5  
columnar epithelium 4, 5  
fundus 4, 5  
oxyntic (acid-producing) mucosa 4, 5  
pylorus 5  
*see also Helicobacter pylori*
- Streptococcus pneumoniae*  
exploitation of immune system 10–11  
interaction with lung epithelium 270, 283–285  
pneumonia pathogen 8, 302–305, 306
- Streptococcus pyogenes*  
integrin-binding afimbrial  
adhesins 161–162  
phage-encoded virulence factors 38  
swarming by bacteria 137–139
- T1SSs *see* type I secretion systems  
T2SSs *see* type II secretion systems  
T3SSs *see* type III secretion systems  
T4SSs *see* type IV secretion systems  
T5SSs *see* type V secretion systems
- tetanus toxin 35
- tight junctions *see* epithelial tight junctions
- TLRs (Toll-like receptors) 100–101, 310–311  
coreceptors 106–107  
defining TLR ligands 104–105, 106  
epithelial barrier modulation 115–117  
expression in lung epithelium 311–314  
in the uroepithelium 403, 407, 413–414  
intracellular 101  
mediation of immune responses 108–109  
pathway of NF- $\kappa$ B activation 247–248  
soluble 103–104  
TLR signaling 106  
TLR2 in airway infection 311–312  
TLR4 in airway infection 312–313  
TLR5 in airway infection 313–314  
TLR5 recognition of flagellin 139–141
- TNFR1 signaling, airway epithelial  
cells 314–315
- Toll-like receptors *see* TLRs
- Toll protein (*Drosophila*) 100–101
- trachea, epithelial cells 8
- transduction process of horizontal gene  
transfer (HGT) 32–33
- transformation process of horizontal gene  
transfer (HGT) 32–33
- transposable elements  
in bacterial pathogenesis 39–40  
in horizontal gene transfer (HGT) 32–33
- transposons 39–40
- tubulin filaments 12, 13
- tumor growth  
inflammation-associated 254–255  
NF- $\kappa$ B activation 254–255
- tumor necrosis factor alpha, role in MLCK  
upregulation 17–18, 20
- type I secretion systems (T1SSs)  
(Gram-negative bacteria) 60–61, 62, 64  
ABC (ATP-binding cassette)  
transporter 60, 61, 62, 62–64  
effector molecules 60–61, 62, 63  
MFP (membrane fusion protein) 60, 61, 62, 62–64  
OMP (outer membrane protein) 60, 61, 62, 62–64
- type II secretion systems (T2SSs)  
(Gram-negative bacteria) 64–66, 68  
effector molecules 64–65  
*gsp*-encoded proteins 65–66, 68  
release of flagellin 139–141
- type III secretion systems (T3SSs)  
(Gram-negative bacteria)  
association with acute invasive  
infection 317–318  
molecular manipulation of host epithelial  
cells 363–365  
non-flagellar 66, 68–75  
*Shigella* 358–359
- type III secretion system in flagella 66, 68, 69, 131–132  
export of non-flagellar proteins 147–149  
role in flagellar biogenesis 140, 141–142
- type IV secretion systems (T4SSs)  
(Gram-negative bacteria) 66, 75–80  
*Agrobacterium tumefaciens* VirB/D4  
system 66, 75–78  
*Bordetella pertussis* PT system 66, 75–76, 77, 78

- type IV secretion systems (T4SSs) (*cont.*)
  - Helicobacter pylori* Cag PAI 66, 75–76, 77, 78–79, 337–338
  - Legionella pneumophila* Dot/Icm system 66, 75–76, 77, 79–80
- type V secretion systems (T5SSs)
  - (Gram-negative bacteria)
  - Va autotransporters (ATs) 80–81, 82, 85
  - Vb two-partner system (TPS) 80–81, 82, 85
  - Vc oligomeric coiled-coil (Oca) system 80–81, 82, 85
- ulcerative colitis 256–257
- UPECs (uropathogenic *Escherichia coli* strains)
  - adhesive structures 405–406
  - attachment to uroepithelium 405–406
  - CNF1 toxin production 410–411, 412–413
  - early events in pathogenicity 405–406
  - fimbrial adhesins 159, 160
  - genetic evidence for virulence 403–404, 405
  - $\alpha$ -hemolysin toxin production 409–411, 412–413
  - host responses to UPEC
    - attachment 407–409
  - invasion of uroepithelial cells 408–409, 413
  - persistence of urinary tract infections 408–409, 412–414
  - prevalence in urinary tract infections 400, 401
  - subversion of host responses 412–413
  - toxins associated with
    - pathogenesis 409–413
  - virulence factors and pathogenicity islands 42, 401, 403–404, 405
- urethra, bacterial infections 9
- urinary tract 8–9
  - bladder 8–9
  - epithelial cells (urothelium) 8–9
  - infection 9
    - acute cystitis 401
    - acute pyelonephritis 401
    - bacterial persistence 408–409, 412–414
    - CNF1 toxin production 410–411, 412–413
    - early events in UPEC pathogenicity 405–406
    - $\alpha$ -hemolysin toxin production 409–411, 413
    - high rate in humans 400
    - levels of spread and severity of infection 401
    - nosocomial acquired infections 400
    - prevalence of UPECs 400, 401
    - risk from catheterization 400
    - risk of recurrence 400
    - swarming in *Proteus mirabilis* 137–139
    - toxins associated with UPEC
      - pathogenesis 409–413
- uroepithelium/urothelium
  - attachment of UPECs 405–406
  - barrier role 401–402, 403
  - cell types 8–9
  - defenses against pathogens 401–402, 403
  - detection of PAMPs 403, 407–409
  - host responses to UPEC
    - attachment 407–409
  - inflammatory response to pathogens 403, 407–409
  - invasion by UPECs 408–409, 413
  - Nod proteins 403
  - structure and functions 401–402, 403
  - TLRs 403, 407, 413–414
  - UPEC subversion of host responses 412–413
  - urothelial carcinoma 8–9
- VacA virulence factor, *Helicobacter pylori* 334–337
- vesicular traffic across epithelia 10–12
- Vibrio cholerae*
  - action of cholera toxin 202
  - disruption of epithelial tight junctions 375–376
  - fimbrial adhesins 160
  - phage-encoded toxin genes 36, 38
  - RtxA actin polymerizing toxin 194–195
  - type II secretion system 64–65
  - virulence factors encoded by pathogenicity islands (PAIs) 42
- virulence genes, regulation 44–45
- virulence plasmid in *Shigella* spp. 46–47
- vitamin B12 absorption, intrinsic factor 4, 5



whooping cough	
<i>see</i> <i>Bordetella pertussis</i>	
<i>Xanthomonas</i> , NF-T3SS	68–70
<i>Xanthomonas campestris</i> , type II secretion system	65
<i>Yersinia enterocolitica</i>	
flagellar export of non-flagellar proteins	147–149
integrin engagement	14, 164–165
type V secretion system	82
<i>Yersinia pestis</i> , non-expression of invasins	164
<i>Yersinia pseudotuberculosis</i>	
inhibition of NF- $\kappa$ B	255–256
integrin engagement	14, 164–165
<i>Yersinia</i> spp.	
disruption of intestinal barrier function	377
host receptor cell exploitation	357–358
infection of the ileum	5–6
NF-T3SS	66, 68–71, 72–75
paradigm of host cell invasion	230–231
plasmid virulence factors	34–35
role of motility in initial infection	132–135
virulence factors encoded by pathogenicity islands (PAIs)	42
YopE cytotoxin	198–199
YopH cytotoxin	199
YopT cytotoxin	196